verview With the increasing frequency of real-time FDA audits and complexity of Investigational Medicinal Products (IMP), the wise are paying more attention to including a full range of lab tests to insure IMP safety. Which lab values outside of the Reference range are to be reported as AE is always a question that must be answered and will be reviewed. The question of the relationship of lab data to FDA Adverse Event reporting system determination is the decision of the Investigator guided by what is in the protocol.

Date : 3rd March 2015 to 3rd March 2015

Place : United States, New hyde park

Website :https://www.complianceglobal.us/product/700002

Contact Person:Compliance Global Inc

Description:

verview With the increasing frequency of real-time FDA audits and complexity of Investigational Medicinal Products (IMP’s), the wise are paying more attention to including a full range of lab tests to insure IMP safety. Which lab values outside of the Reference range are to be reported as AE’s is always a question that must be answered and will be reviewed. The question of the relationship of lab data to “FDA Adverse Event reporting system” determination is the decision of the Investigator guided by what is in the protocol.

verview With the increasing frequency of real-time FDA audits and complexity of Investigational Medicinal Products (IMP), the wise are paying more attention to including a full range of lab tests to insure IMP safety. Which lab values outside of the Reference range are to be reported as AE is always a question that must be answered and will be reviewed. The question of the relationship of lab data to FDA Adverse Event reporting system determination is the decision of the Investigator guided by what is in the protocol. will be held in New hyde park,United States on date 2015-03-03

---

Deadline for abstracts/proposals : 3rd March 2015

Keynote Speakers :

Check the event website for more details.